Tucker Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Tucker Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,442	Closed	-$5.9K	–	892
2025 Q4	$5.9K	Buy	+1,442	New	+$7.14K	﹤0.01%	669
2025 Q1	–	Sell	-1,442	Closed	-$9.75K	–	806
2024 Q4	$9.75K	Buy	+1,442	New	+$9.7K	﹤0.01%	771
2024 Q2	–	Sell	-3,091	Closed	-$30.8K	–	1776
2024 Q1	$30.8K	Buy	3,091 +3,000	+3,297%	+$33.4K	0.01%	554
2023 Q4	$897	Hold	91	–	–	﹤0.01%	1267
2023 Q3	$696	Hold	91	–	–	﹤0.01%	1227
2023 Q2	$680	Hold	91	–	–	﹤0.01%	1009
2023 Q1	$607	Buy	+91	New	+$722	﹤0.01%	1036
2022 Q2	–	Sell	-30	Closed	-$215	–	693
2022 Q1	$215	Buy	+30	New	+$319	﹤0.01%	546

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tucker Asset Management's RXRX Position: Q1 2026 in Review

Tucker Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 1,442 shares — an estimated $5.9K sold.

Tucker Asset Management first reported a position in RXRX in Q1 2022 and held it in 8 quarters. The position peaked at $30.8K in Q1 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Tucker Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Tucker Asset Management sold 1,442 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.9K.
Tucker Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 8 quarters.
Tucker Asset Management's Recursion Pharmaceuticals position peaked at $30.8K in Q1 2024.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Tucker Asset Management's 13F filing for Q1 2026, filed 27 Aug 2026.